Marex Group’s PTC Therapeutics PTCT Stock Holding History

Marex Group’s Portfolio PTCT Stock Details PTCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-9,334	Closed	-$636K	–	1301
2026 Q1	$636K	Buy	+9,334	New	+$661K	﹤0.01%	562
2025 Q4	–	Sell	-3,692	Closed	-$227K	–	1108
2025 Q3	$227K	Buy	+3,692	New	+$192K	﹤0.01%	686

Other funds holding PTCT

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Jupiter Topco New York $245B AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $86.4B AUM 59.51% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return

Marex Group's PTCT Position: Q2 2026 in Review

Marex Group sold out of PTC Therapeutics (PTCT) in Q2 2026, closing a stake of 9,334 shares — an estimated $636K sold.

Marex Group first reported a position in PTCT in Q3 2025 and held it in 2 quarters. The position peaked at $636K in Q1 2026. 382 funds tracked by Wall St. Rank hold PTCT as of Q2 2026.

Marex Group reported no remaining PTC Therapeutics position as of Q2 2026 after selling out during the quarter.
Marex Group sold 9,334 PTC Therapeutics shares in Q2 2026, an estimated $636K.
Marex Group first reported a position in PTC Therapeutics in Q3 2025 and held it in 2 quarters.
Marex Group's PTC Therapeutics position peaked at $636K in Q1 2026.
382 funds tracked by Wall St. Rank held PTC Therapeutics as of Q2 2026.

Based on Marex Group's 13F filing for Q2 2026, filed 14 Aug 2026.